GlassScriptPhysician profile
Robert Alan Wilson
NPI 1699782557
$887.60
in general payments reported to CMS, 2019-2025
24 companies · $172 in 2025
The $172 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $122 · 2020: $19.38 · 2021: $26.62 · 2022: $275 · 2023: $89.84 · 2024: $183 · 2025: $172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $445 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $444.51 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $186.31 | 2022 | |
| Medtronic, INC. | $113.30 | 2022-2024 | Minimed 780g |
| Novo Nordisk INC | $108.29 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $60.42 | 2024-2025 | Zepbound, Mounjaro |
| Abbvie INC. | $42.40 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $34.38 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $32.28 | 2025 | Farxiga, Breztri |
| Glaxosmithkline, LLC. | $30.91 | 2023-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Pfizer INC. | $30.31 | 2019 | |
| Hologic Sales and Service, LLC | $24.55 | 2025 | Aptima |
| Otsuka America Pharmaceutical, INC. | $22.30 | 2024 | Rexulti |
| Phathom Pharmaceuticals, INC. | $20.52 | 2025 | Voquezna |
| Avanir Pharmaceuticals, INC. | $20.41 | 2022 | |
| Merck Sharp & Dohme LLC | $20.22 | 2025 | Vaxneuvance, Gardasil 9, Enflonsia |
| Abbott Laboratories | $19.38 | 2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $17.89 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $17.49 | 2025 | Dojolvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.33 | 2019 | |
| Janssen Pharmaceuticals, INC | $15.62 | 2019 | |
| Exact Sciences Corporation | $15.28 | 2024 | Cologuard Collection Kit |
| Mylan Specialty L.P. | $13.30 | 2019 | |
| Neurelis, INC. | $13.11 | 2023 | Valtoco |
| Sanofi Pasteur INC. | $11.81 | 2019 | |
| Sumitomo Pharma America, INC. | $0.79 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.